Omar Abdel-Wahab: Initial Data on IL-18 CD371 CAR T in AML
Omar Abdel-Wahab, Hematologist/Oncologist, Director of MSK Center for Hematologic Malignancies, and Chair of Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Blood:
“Congratulations to Anthony F. Daniyan and team from Memorial Sloan Kettering Cancer Center on the publication of the initial data from AML patients treated with IL-18 secreting CD371 CAR T cells.
3/5 patients experienced MRD-negative morphologic leukemia-free state.”
Title: CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia
Authors: Mark B. Geyer, Susan DeWolf, Xiaoli Mi, Kenyon Weis, Brian C. Shaffer, Briana Cadzin, Devin McAvoy, Zoe A Katsamakis, Rachel Lorenc, Alexander M Lewis, Brianna Gipson, M. Adriana Cuibus, Narina N. Girotra, Kenton Wu, Natalie Smith, Erin R. Burns, Jasmine S. Um, Sarah Yoo, Behzad Kharabi Masouleh, Pallavi K. Galera, Kinga Hosszu, Jagrutiben Chaudhari, Xiuyan Wang, Qianqian Lin, Kevin J. Curran, Jae H Park, David A Scheinberg, Marcel R.M. van den Brink, Omar Abdel-Wahab, Renier J. Brentjens, Anthony F. Daniyan
You can read the Full Article on Blood.
More posts featuring Omar Abdel-Wahab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023